PIK3CA and head and neck squamous cell carcinoma: A phase Ib/II study (COPAN-ORL06) sponsored by UNICANCER is assessing the MTD, efficacy and RP2D of Copanlisib in combination with Cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) with a PIK3CA mutation/amplification and/or a PTEN loss [177].